{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:08:30Z","timestamp":1790806110080,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite the prevalence of various infectious and pandemic diseases worldwide, cancer remains the leading cause of death. Clinical approaches for treating cancer vary depending on the tumor type and aggressiveness, including surgery, chemo-, radio-, immune- and hormone therapies. However, the efficacy of these treatments is hindered by the high mortality rate during chemotherapy and radiotherapy, primarily due to severe side effects.This experimental study was conducted on 40 female Sprague-Dawley (SD) rats (n=8). A metronomic treatment strategy was employed using intraperitoneal administration of a small dose of capecitabine loaded onto silica nanoparticles (Cap@SNPs) (377mg\/kg) once weekly for a month, either singly or in combination with a low dose of gamma ionizing radiation (IR) (0.5 Gy\/5 days) over six sessions, against a 7,12-dimethylbenz[a]anthracene (DMBA) induced mammary carcinoma model in SD rats. The antitumor effect of Cap@SNPs and\/or \u03b3-radiation was assessed by tumor volume measurements, survival analysis, biochemical and haematological parameters and gene expression profiling of selected apoptotic and anti-apoptotic genes. Cell cycle phase distribution, apoptotic cells (Annexin V) and the expression of some immunomodulatory proteins were analyzed by flow cytometry. Histopathological examination was performed using hematoxylin and eosin (H&amp;E) staining. The expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2\/neu) proteins in mammary tissue was assessed by immunohistochemistry (IHC). The initial tumor volume across all groups was 32.8\u2009\u00b1\u20091.8 mm\n                    <jats:sup>3<\/jats:sup>\n                    , reaching 86\u2009\u00b1\u20091.9 mm\n                    <jats:sup>3<\/jats:sup>\n                    in the positive control at Day 30 but only 5.3\u2009\u00b1\u20090.5 mm\n                    <jats:sup>3<\/jats:sup>\n                    in the Cap@SNPs\u2009+\u2009IR group. The death rate decreased from 75% in the positive control to 12.5% in the combined-treated group. Gene expression analysis revealed the downregulation and upregulation of the anti-apoptotic gene (\n                    <jats:italic>Bcl2<\/jats:italic>\n                    ) and the apoptotic genes (\n                    <jats:italic>Bax<\/jats:italic>\n                    ,\n                    <jats:italic>Fas<\/jats:italic>\n                    and\n                    <jats:italic>Caspase-8<\/jats:italic>\n                    ), respectively, in the combination therapy. Flow cytometric analysis showed cell cycle arrest at the G1 phase and increased early apoptosis in the combined-treated group. The findings were verified by histopathological examination and immunohistochemical analysis of mammary\u00a0tumor tissues. In conclusion, administration of a small\u00a0capecitabine dose via silica nanoparticle delivery, along with fractionated radiotherapy, achieved substantial tumor regression, improved survival and effective cell-cycle arrest in mammary tumor-bearing rats. These findings support the integration of metronomic chemotherapy with nanoscale drug delivery systems and fractionated radiotherapy as a promising multimodal strategy to enhance anti-tumor efficacy, reduce dose-related toxicity and ultimately improve therapeutic outcomes.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-026-02099-5","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:04:06Z","timestamp":1778871846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemotherapeutic efficacy of nano formulation capecitabine@SNPs and gamma radiation: a novel metronomic approach for breast cancer treatment"],"prefix":"10.1007","author":[{"given":"Marwa I.","family":"Ghanim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Y.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayda K.","family":"Kelany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa A.","family":"Askar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Gharib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-3283","authenticated-orcid":false,"given":"Heba K.","family":"Abdelhakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"1","key":"2099_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2099_CR2","first-page":"7071","volume":"89","author":"AM Saad","year":"2022","unstructured":"Saad AM, Hussein MA, El-Afandey A. Perception of female health care providers regarding breast cancer at El Minia Oncology Center. 2022. 2022;89(2):7071\u201381.","journal-title":"2022"},{"issue":"3","key":"2099_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2099_CR4","unstructured":"Alorabi M, et al.\u00a0Cancer control in Egypt: Investing in health. The ASCO Post, 2021."},{"key":"2099_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3","author":"J Kim","year":"2025","unstructured":"Kim J, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03502-3.","journal-title":"Nat Med"},{"issue":"3","key":"2099_CR6","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/cancers3033279","volume":"3","author":"M Arruebo","year":"2011","unstructured":"Arruebo M, et al. Assessment of the evolution of cancer treatment therapies. Cancers. 2011;3(3):3279\u2013330.","journal-title":"Cancers"},{"key":"2099_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.toxlet.2022.09.013","volume":"371","author":"D Rodrigues","year":"2022","unstructured":"Rodrigues D, et al. Gene expression responses reflecting 5-FU-induced toxicity: comparison between patient colon tissue and 3D human colon organoids. Toxicol Lett. 2022;371:17\u201324.","journal-title":"Toxicol Lett"},{"issue":"3","key":"2099_CR8","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.12968\/bjon.2020.29.3.S4","volume":"29","author":"S McCauley","year":"2020","unstructured":"McCauley S, et al. Pharmacotherapeutics of capecitabine and trastuzumab in the treatment of metastatic breast cancer. Br J Nurs. 2020;29(3):S4\u20139.","journal-title":"Br J Nurs"},{"issue":"5","key":"2099_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/CAD.0b013e3282f945aa","volume":"19","author":"MW Saif","year":"2008","unstructured":"Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs. 2008;19(5):447\u201364.","journal-title":"Anticancer Drugs"},{"issue":"11","key":"2099_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","volume":"13","author":"G Bocci","year":"2016","unstructured":"Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13(11):659\u201373.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2099_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.canlet.2014.08.028","volume":"354","author":"Y-B Hao","year":"2014","unstructured":"Hao Y-B, et al. New insights into metronomic chemotherapy-induced immunoregulation. Cancer Lett. 2014;354(2):220\u20136.","journal-title":"Cancer Lett"},{"issue":"2","key":"2099_CR12","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5601","volume":"64","author":"H Liu","year":"2023","unstructured":"Liu H, et al. Dual-directional effect of vinorelbine combined with cisplatin or fluorouracil on tumor growth and metastasis in metronomic chemotherapy in breast cancer. Int J Oncol. 2023;64(2):13.","journal-title":"Int J Oncol"},{"issue":"21","key":"2099_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/nano13212887","volume":"13","author":"M Sell","year":"2023","unstructured":"Sell M, et al. Application of nanoparticles in cancer treatment: a concise review. Nanomaterials. 2023;13(21):2887.","journal-title":"Nanomaterials"},{"issue":"8","key":"2099_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17080987","volume":"17","author":"RNA Kazi","year":"2025","unstructured":"Kazi RNA, et al. Nanomedicine: the effective role of nanomaterials in healthcare from diagnosis to therapy. Pharmaceutics. 2025;17(8):987.","journal-title":"Pharmaceutics"},{"issue":"2","key":"2099_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.47162\/RJME.65.2.03","volume":"65","author":"C-L Nicolae","year":"2024","unstructured":"Nicolae C-L, et al. Silica nanoparticles in medicine: overcoming pathologies through advanced drug delivery, diagnostics, and therapeutic strategies. Rom J Morphol Embryol. 2024;65(2):173.","journal-title":"Rom J Morphol Embryol"},{"key":"2099_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fnano.2025.1564188","volume":"7","author":"R Fatima","year":"2025","unstructured":"Fatima R, Katiyar P, Kushwaha K. Recent advances in mesoporous silica nanoparticle: synthesis, drug loading, release mechanisms, and diverse applications. Frontiers in Nanotechnology. 2025;7:1564188.","journal-title":"Frontiers in Nanotechnology"},{"issue":"13","key":"2099_CR17","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1039\/D1CS00659B","volume":"51","author":"M Vallet-Reg\u00ed","year":"2022","unstructured":"Vallet-Reg\u00ed M, et al. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem Soc Rev. 2022;51(13):5365\u2013451.","journal-title":"Chem Soc Rev"},{"issue":"1","key":"2099_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/molecules23010047","volume":"23","author":"M Vallet-Reg\u00ed","year":"2017","unstructured":"Vallet-Reg\u00ed M, et al. Mesoporous silica nanoparticles for drug delivery: current insights. Molecules. 2017;23(1):47.","journal-title":"Molecules"},{"issue":"12","key":"2099_CR19","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3390\/pharmaceutics17121602","volume":"17","author":"A Almatroudi","year":"2025","unstructured":"Almatroudi A. Advances in mesoporous silica and hybrid nanoparticles for drug delivery: synthesis, functionalization, and biomedical applications. Pharmaceutics. 2025;17(12):1602.","journal-title":"Pharmaceutics"},{"issue":"9","key":"2099_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ph18091392","volume":"18","author":"F Benk\u0151","year":"2025","unstructured":"Benk\u0151 F, Krist\u00f3 K, Sov\u00e1ny T. Mesoporous silica nanoparticles as drug delivery systems. Pharmaceuticals. 2025;18(9):1392.","journal-title":"Pharmaceuticals"},{"issue":"12","key":"2099_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125850","volume":"26","author":"A Mosseri","year":"2025","unstructured":"Mosseri A, et al. A review of silica-based nanoplatforms for anticancer cargo delivery. Int J Mol Sci. 2025;26(12):5850.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2099_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70346","volume":"6","author":"X Wang","year":"2025","unstructured":"Wang X, Jing J. Cancer immunotherapy in combination with radiotherapy and\/or chemotherapy: mechanisms and clinical therapy. MedComm. 2025;6(9):e70346.","journal-title":"MedComm"},{"issue":"5","key":"2099_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051482","volume":"15","author":"E Le Reun","year":"2023","unstructured":"Le Reun E, Foray N. Low-dose radiation therapy (LDRT) against cancer and inflammatory or degenerative diseases: three parallel stories with a common molecular mechanism involving the nucleoshuttling of the ATM protein? Cancers. 2023;15(5):1482.","journal-title":"Cancers"},{"issue":"1","key":"2099_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3233\/TUB-211506","volume":"43","author":"MA Askar","year":"2021","unstructured":"Askar MA, et al. Breast cancer suppression by curcumin-naringenin-magnetic-nano-particles: in vitro and in vivo studies. Tumor Biol. 2021;43(1):225\u201347.","journal-title":"Tumor Biol"},{"key":"2099_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101710","volume":"35","author":"L Gao","year":"2023","unstructured":"Gao L, Zhang A. Low-dose radiotherapy effects the progression of anti-tumor response. Transl Oncol. 2023;35:101710.","journal-title":"Transl Oncol"},{"issue":"13","key":"2099_CR26","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1021\/ja211035w","volume":"134","author":"L Pan","year":"2012","unstructured":"Pan L, et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J Am Chem Soc. 2012;134(13):5722\u20135.","journal-title":"J Am Chem Soc"},{"issue":"6","key":"2099_CR27","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ddr.21570","volume":"80","author":"J Rajendran","year":"2019","unstructured":"Rajendran J, Pachaiappan P, Subramaniyan S. Dose\u2010dependent chemopreventive effects of citronellol in DMBA\u2010induced breast cancer among rats. Drug Dev Res. 2019;80(6):867\u201376.","journal-title":"Drug Dev Res"},{"issue":"6","key":"2099_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067330","volume":"8","author":"A Courtin","year":"2013","unstructured":"Courtin A, et al. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PLoS One. 2013;8(6):e67330.","journal-title":"PLoS One"},{"issue":"6","key":"2099_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/laban.254","volume":"42","author":"A Faustino-Rocha","year":"2013","unstructured":"Faustino-Rocha A, et al. Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Anim. 2013;42(6):217\u201324.","journal-title":"Lab Anim"},{"key":"2099_CR30","doi-asserted-by":"crossref","unstructured":"Plowman J. Human tumor xenograft models in NCI drug development. In: Anticancer drug development guide: preclinical screening, clinical trials, and approval. Springer; 1997. p. 101\u201325.","DOI":"10.1007\/978-1-4615-8152-9_6"},{"issue":"4","key":"2099_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.21608\/jmals.2019.180380","volume":"1","author":"L Dawood","year":"2019","unstructured":"Dawood L, et al. Anti-proliferative effect of ZnO NPs against the growth of Ehrlich Solid carcinoma. J Med Life Sci. 2019;1(4):110\u201322.","journal-title":"J Med Life Sci"},{"issue":"1","key":"2099_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/ajcp\/28.1.56","volume":"28","author":"S Reitman","year":"1957","unstructured":"Reitman S, Frankel SJA. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28(1):56\u201363.","journal-title":"Am J Clin Pathol"},{"issue":"82","key":"2099_CR33","first-page":"464","volume":"49","author":"C Patton","year":"1977","unstructured":"Patton C, Crouch SJAC. Enzymatic determination of urea. 1977;49(82):464\u20139.","journal-title":"Enzymatic determination of urea"},{"issue":"5","key":"2099_CR34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/clinchem\/26.5.555","volume":"26","author":"LD Bowers","year":"1980","unstructured":"Bowers LD, Wong E. Kinetic serum creatinine assays. II. a critical evaluation and review. Clin Chem. 1980;26(5):555\u201361.","journal-title":"Clin Chem"},{"key":"2099_CR35","first-page":"499","volume":"107","author":"TA Pearson","year":"2003","unstructured":"Pearson TA, et al. AHA\/CDC scientific statement. 2003;107:499\u2013511.","journal-title":"AHA\/CDC scientific statement"},{"issue":"2","key":"2099_CR36","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/ijc.2910070205","volume":"7","author":"E Ruoslahti","year":"1971","unstructured":"Ruoslahti E, Sepp\u00e4l\u00e4 M. Studies of carcino\u2010fetal proteins: physical and chemical properties of human \u03b1\u2010fetoprotein. Int J Cancer. 1971;7(2):218\u201325.","journal-title":"Int J Cancer"},{"issue":"5","key":"2099_CR37","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1172\/JCI110380","volume":"68","author":"RC Bast","year":"1981","unstructured":"Bast RC, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331\u20137.","journal-title":"J Clin Invest"},{"issue":"2","key":"2099_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5455\/jppa.20130228054608","volume":"3","author":"H El-Banna","year":"2013","unstructured":"El-Banna H, Soliman M, Al-Wabel NJJPPA. Hepatoprotective effects of Thymus and Salvia essential oils on paracetamol-induced toxicity in rats. J Physiol Pharmacol. 2013;3(2):41\u20137.","journal-title":"Journal of Physiology and Pharmacology Advances"},{"issue":"1","key":"2099_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0009-8981(78)90081-5","volume":"90","author":"S Kei","year":"1978","unstructured":"Kei S. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta. 1978;90(1):37\u201343.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"2099_CR40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1182\/blood.V88.2.386.bloodjournal882386","volume":"88","author":"E Yang","year":"1996","unstructured":"Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996;88(2):386\u2013401.","journal-title":"Blood"},{"key":"2099_CR41","unstructured":"Bancroft JD, Gamble M. Theory and practice of histological techniques. Elsevier Health Sciences, 6th ed. Philadelphia, PA. Vol. 1. 2008.\u00a0Elsevier Health Sciences."},{"issue":"8","key":"2099_CR42","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1021\/acsbiomaterials.1c00514","volume":"7","author":"AK Singh","year":"2021","unstructured":"Singh AK, et al. Lipid-coated MCM-41 mesoporous silica nanoparticles loaded with berberine improved inhibition of acetylcholine esterase and amyloid formation. ACS Biomater Sci Eng. 2021;7(8):3737\u201353.","journal-title":"ACS Biomater Sci Eng"},{"key":"2099_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.partic.2014.06.007","volume":"19","author":"K Panwar","year":"2015","unstructured":"Panwar K, Jassal M, Agrawal AKJP. In situ synthesis of Ag\u2013SiO2 Janus particles with epoxy functionality for textile applications. Particuology. 2015;19:107\u201312.","journal-title":"Particuology"},{"key":"2099_CR44","unstructured":"Cipurkovi\u0107 A, et al. Synthesis and spectral characterization of Fe (II) and Mn (II) complexes with oral fluorouracil pro-drug Capecitabine. RASAYAN Journal of Chemistry, 2017;10(4):1381\u20131390."},{"key":"2099_CR45","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00280-011-1628-6","volume":"68","author":"N Frances","year":"2011","unstructured":"Frances N, et al. Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Cancer Chemother Pharmacol. 2011;68:1413\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2099_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011220.pub2","author":"AM White","year":"2021","unstructured":"White AM, et al. Capecitabine for hormone receptor\u2010positive versus hormone receptor\u2010negative breast cancer. Cochrane Database Syst Rev. 2021. https:\/\/doi.org\/10.1002\/14651858.CD011220.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2099_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899423","volume":"12","author":"X Xun","year":"2022","unstructured":"Xun X, et al. Efficacy and safety of capecitabine for triple-negative breast cancer: a meta-analysis. Front Oncol. 2022;12:899423.","journal-title":"Front Oncol"},{"key":"2099_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1746-1596-8-150","volume":"8","author":"S Gurzu","year":"2013","unstructured":"Gurzu S, et al. Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman. Diagn Pathol. 2013;8:1\u20135.","journal-title":"Diagn Pathol"},{"issue":"19","key":"2099_CR49","doi-asserted-by":"publisher","first-page":"17738","DOI":"10.18632\/oncotarget.3921","volume":"6","author":"C Dai","year":"2015","unstructured":"Dai C, et al. Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. Oncotarget. 2015;6(19):17738.","journal-title":"Oncotarget"},{"issue":"1","key":"2099_CR50","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1159\/000529866","volume":"16","author":"M Hussein","year":"2023","unstructured":"Hussein M, Jensen AB. Drug-induced liver injury caused by capecitabine: a case report and a literature review. Case Rep Oncol. 2023;16(1):393\u20139.","journal-title":"Case Rep Oncol"},{"issue":"7","key":"2099_CR51","first-page":"1696","volume":"5","author":"C Twelves","year":"1999","unstructured":"Twelves C, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res. 1999;5(7):1696\u2013702.","journal-title":"Clin Cancer Res"},{"issue":"46","key":"2099_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008547","volume":"96","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, et al. Reversible severe fatty liver induced by capecitabine: a case report. Medicine (Baltimore). 2017;96(46):e8547.","journal-title":"Medicine (Baltimore)"},{"key":"2099_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70041","author":"Y Song","year":"2025","unstructured":"Song Y, et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high\u2010risk, HER2\u2010negative breast cancer: an open\u2010label, randomized controlled trial. Cancer Commun. 2025. https:\/\/doi.org\/10.1002\/cac2.70041.","journal-title":"Cancer Commun"},{"key":"2099_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102283","volume":"100","author":"RR Saleh","year":"2021","unstructured":"Saleh RR, et al. Platinum-based chemotherapy in early-stage triple negative breast cancer: a meta-analysis. Cancer Treat Rev. 2021;100:102283.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2099_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/medicines4040078","volume":"4","author":"ET Olayinka","year":"2017","unstructured":"Olayinka ET, et al. Ameliorative effect of caffeic acid on capecitabine-induced hepatic and renal dysfunction: involvement of the antioxidant defence system. Medicines. 2017;4(4):78.","journal-title":"Medicines"},{"issue":"39","key":"2099_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202303269","volume":"20","author":"S Mohanan","year":"2024","unstructured":"Mohanan S, et al. Design and synthesis of cabazitaxel loaded core\u2010shell mesoporous silica nanoparticles with different morphologies for prostate cancer therapy. Small. 2024;20(39):2303269.","journal-title":"Small"},{"key":"2099_CR57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2165\/00003495-200363020-00009","volume":"63","author":"AJ Wagstaff","year":"2003","unstructured":"Wagstaff AJ, Ibbotson T, Goa KLJD. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs. 2003;63:217\u201336.","journal-title":"Drugs"},{"key":"2099_CR58","doi-asserted-by":"crossref","unstructured":"Del Poeta G. et al.\u00a0Amount of spontaneous apoptosis detected by Bax\/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) Presented in part at the 42nd annual meeting of the American Society of Hematology, San Francisco, CA, December 1\u20135, 2000.46. Blood. 2003;101(6):2125\u201331.","DOI":"10.1182\/blood-2002-06-1714"},{"issue":"2","key":"2099_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020257","volume":"16","author":"S Seyedi","year":"2024","unstructured":"Seyedi S, et al. Testing adaptive therapy protocols using gemcitabine and capecitabine in a preclinical model of endocrine-resistant breast cancer. Cancers. 2024;16(2):257.","journal-title":"Cancers"},{"key":"2099_CR60","doi-asserted-by":"publisher","DOI":"10.52973\/rcfcv-e33254","author":"R Canbar","year":"2023","unstructured":"Canbar R, Ozdemir O, Levent Bas A. Effect of Tarantula cubensis alcohol extract and capecitabin combine in colorectal cancer rats. Rev Cient Fac Cienc Vet. 2023. https:\/\/doi.org\/10.52973\/rcfcv-e33254.","journal-title":"Rev Cient Fac Cienc Vet"},{"key":"2099_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-017-0647-5","volume":"36","author":"M Terranova-Barberio","year":"2017","unstructured":"Terranova-Barberio M, et al. Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. J Exp Clin Cancer Res. 2017;36:1\u201313.","journal-title":"J Exp Clin Cancer Res"},{"issue":"22","key":"2099_CR62","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1158\/0008-5472.CAN-16-3167","volume":"77","author":"BA Kansy","year":"2017","unstructured":"Kansy BA, et al. PD-1 status in CD8+ T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res. 2017;77(22):6353\u201364.","journal-title":"Cancer Res"},{"issue":"5","key":"2099_CR63","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0952-7915(98)80228-8","volume":"10","author":"DM Pardoll","year":"1998","unstructured":"Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 1998;10(5):588\u201394.","journal-title":"Curr Opin Immunol"},{"key":"2099_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1368550","volume":"15","author":"M Gouez","year":"2024","unstructured":"Gouez M, et al. Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal cancer-bearing mice. Front Immunol. 2024;15:1368550.","journal-title":"Front Immunol"},{"issue":"1","key":"2099_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng Z, et al. TGF-\u03b2 signaling in health, disease and therapeutics. Signal Transduct Target Ther. 2024;9(1):61.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2099_CR66","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/cei.13357","volume":"199","author":"G Deng","year":"2020","unstructured":"Deng G, Song X, Greene M. Foxp3 in Treg cell biology: a molecular and structural perspective. Clin Exp Immunol. 2020;199(3):255\u201362.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2099_CR67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10549-010-0831-1","volume":"125","author":"S Ladoire","year":"2011","unstructured":"Ladoire S, et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011;125(1):65\u201372.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"2099_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121606","volume":"17","author":"V Toprak","year":"2024","unstructured":"Toprak V, et al. Modulation of FOXP3 gene expression in OVCAR3 cells following rosmarinic acid and doxorubicin exposure. Pharmaceuticals. 2024;17(12):1606.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"2099_CR69","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3892\/br.2016.694","volume":"5","author":"J Wang","year":"2016","unstructured":"Wang J, Yang JJBR. Identification of CD4+ CD25+ CD127\u2011regulatory T cells and CD14+ HLA\u2011DR\u2011\/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer. Biomed Rep. 2016;5(2):208\u201312.","journal-title":"Biomed Rep"},{"issue":"10","key":"2099_CR70","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00044-024-03296-y","volume":"33","author":"S Iqbal","year":"2024","unstructured":"Iqbal S, et al. Anticancer potential of delphinidin and its derivatives: therapeutic and mechanistic insights. Med Chem Res. 2024;33(10):1769\u201386.","journal-title":"Med Chem Res"},{"issue":"1","key":"2099_CR71","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00262-008-0530-5","volume":"58","author":"F Mozaffari","year":"2009","unstructured":"Mozaffari F, et al. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and\/or radiotherapy in breast cancer: a longitudinal study. Cancer Immunol Immunother. 2009;58(1):111\u201320.","journal-title":"Cancer Immunol Immunother"},{"key":"2099_CR72","doi-asserted-by":"crossref","unstructured":"Pegram M, Jackisch C, Johnston SR. Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer. NPJ Breast Cancer. 2023;9(1):45.","DOI":"10.1038\/s41523-023-00533-2"},{"issue":"6","key":"2099_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02389-3","volume":"41","author":"K Altundag","year":"2024","unstructured":"Altundag K. Benefits of capecitabine in hormone receptor-positive compared to hormone receptor\u2010negative HER2 normal metastatic breast cancer. Med Oncol. 2024;41(6):146.","journal-title":"Med Oncol"},{"key":"2099_CR74","unstructured":"Abdelrahman, I.Y., H. El-Kashef, and N.H. Hassan, Anti-tumor effect of green tea extract, simvastatin and gamma radiation on solid tumor in mice. Arab J Nucl Sci Appl. 2020;53(4):39\u201352."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02099-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02099-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02099-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:02:10Z","timestamp":1778875330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02099-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":74,"alternative-id":["2099"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02099-5","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"All the authors gave their consent for publication of this manuscript in this journal and the work has not been published and is not being considered for publication elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study protocol was approved by the Research Ethics Committee of the National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority (under the serial number: F\/50A\/23).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal ethics"}},{"value":"No potential conflict of interest was declared by the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}